Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Center for Infectious and Inflammatory Diseases, Texas A&M University, Houston, TX, United States.
Front Immunol. 2021 Feb 23;12:608498. doi: 10.3389/fimmu.2021.608498. eCollection 2021.
Liver cirrhosis is one major cause of mortality in the clinic, and treatment of this disease is an arduous task. The scenario will be even getting worse with increasing alcohol consumption and obesity in the current lifestyle. To date, we have no medicines to cure cirrhosis. Although many etiologies are associated with cirrhosis, abnormal intestinal microbe flora (termed dysbiosis) is a common feature in cirrhosis regardless of the causes. Toll-like receptors (TLRs), one evolutional conserved family of pattern recognition receptors in the innate immune systems, play a central role in maintaining the homeostasis of intestinal microbiota and inducing immune responses by recognizing both commensal and pathogenic microbes. Remarkably, recent studies found that correction of intestinal flora imbalance could change the progress of liver cirrhosis. Therefore, correction of intestinal dysbiosis and targeting TLRs can provide novel and promising strategies in the treatment of liver cirrhosis. Here we summarize the recent advances in the related topics. Investigating the relationship among innate immunity TLRs, intestinal flora disorders, and liver cirrhosis and exploring the underlying regulatory mechanisms will assuredly have a bright future for both basic and clinical research.
肝硬化是临床上导致死亡的主要原因之一,而治疗这种疾病是一项艰巨的任务。在当前的生活方式中,随着酒精消费和肥胖的增加,这种情况将会更加恶化。迄今为止,我们还没有治愈肝硬化的药物。尽管许多病因与肝硬化有关,但无论病因如何,异常的肠道微生物菌群(称为菌群失调)是肝硬化的一个共同特征。Toll 样受体(TLR)是先天免疫系统中进化上保守的模式识别受体家族之一,通过识别共生菌和病原菌,在维持肠道微生物群的内稳态和诱导免疫反应方面发挥着核心作用。值得注意的是,最近的研究发现,纠正肠道菌群失衡可以改变肝硬化的进展。因此,纠正肠道菌群失调和靶向 TLR 可以为肝硬化的治疗提供新的有前途的策略。在这里,我们总结了相关主题的最新进展。研究先天免疫 TLRs、肠道菌群紊乱与肝硬化之间的关系,探索其潜在的调节机制,必将为基础和临床研究带来光明的前景。